US pharmaceutical company Pfizer announced on Tuesday that it expects to turn over $ 15 billion in 2021 with its COVID-19 coronavirus vaccine developed with BioNTech. which accounts for about 25% of their business forecasts.
Pfizer, which reported on its quarterly and cumulative results this morning, noted that its total revenue forecast is between $ 59,000 and $ 61 billion for the full year, A figure that reflects the progressive vaccination of countries and their economic recovery.
In 2020, the company made a profit of nine thousand 616 million dollars, 41% lower than the previous year, while its revenues increased slightly by 2%, to 41 billion 908 million, mainly thanks to sales of its oncology and internal medicine products.
“Our ability to move fast and use cutting-edge science to help cut the world’s most important medical challenges was tested by the COVID-19 pandemic. Our record success in developing a vaccine , alongside our partner BioNTech, is just one example of what this new Pfizer is capable of doing, ”said its chief executive, Albert Bourla.
The COVID-19 vaccine developed by Pfizer and BioNTech was the first in the world two months ago to get approval for emergency use by authorities in the UK, and now has the green light in more than half a hundred countries, but the problems have shifted to their distribution.
Pfizer has noted that it has agreed to supply 200 million doses with the EU government and advanced its delivery date to “late May” when it had previously spoken of July, while in the cases of the European Union, in the which has agreed to supply 300 million doses, and the COVAX platform, 40 million doses, did not specify the dates.
The pharmacist on the other hand has reiterated that her vaccine has shown high efficacy against new virus variants in her experiments, which “do not indicate the need for a new vaccine,” but said she is “ready to respond “if these” demonstrate evidence of escaping immunity “of his preparation.
As for its financial results, Pfizer already recorded an improvement in its figures in the fourth quarter of 2020, including first sales of the vaccine that generated $ 154 million.
Between October and December, the pharmaceutical company made a profit of 594 million, reversing the losses of 337 million that it suffered in the same stretch of 2019, And had a turnover of 11 billion 684 million, 12% higher year-on-year.
During the quarter, Pfizer completed the merger operation announced in 2019 between its Upjohn business and GlaxoSmithKline’s Mylan firm, with which they have created a new generic drug maker called Viatris.
For the year as a whole, half of sales were for oncology products (almost $ 11 billion, up 21%) and internal medicine (nine billion, up 2%).
Pfizer’s vaccine division grossed about 6,500 million (2% more) and the most projected was rare diseases, which grew 29% to nearly three billion.
Pfizer raised its earnings per share forecast in 2021 “mainly due to further refinements of the COVID-19 vaccine billing outlook to a range of $ 3.10 to $ 3.20, above the 3 to 3.10 that had announced in mid-January.
The results were mixed on Wall Street and at the start of the session its shares were down close to 3%. In the last year, they have lost 3% of their value.
OA
